| John J Strobel, MD | |
|
3100 Channing Way, Idaho Falls, ID 83404-7533 | |
| (208) 529-6111 | |
| Not Available |
| Full Name | John J Strobel |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 35 Years |
| Location | 3100 Channing Way, Idaho Falls, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497834980 | NPI | - | NPPES |
| 300072298 | Other | RAILROAD MEDICARE | |
| 003920800 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | M6435 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Portneuf Medical Center | Pocatello, ID | Hospital |
| Eastern Idaho Regional Medical Center | Idaho falls, ID | Hospital |
| Mountain View Hospital | Idaho falls, ID | Hospital |
| Deer Lodge Medical Center - Cah | Deer lodge, MT | Hospital |
| Steele Memorial Medical Center | Salmon, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cache Valley Vein | 5294069563 | 8 |
| Medical Imaging Associates Of Idaho Falls Inc | 7618876590 | 70 |
| Teton Radiology Diagnostic A Series Of Teton Group Enterprise | 1254436959 | 33 |
| Teton Radiology Madison Llc | 6901958024 | 31 |
| Cache Valley Vein | 5294069563 | 8 |
| Medical Imaging Associates Of Idaho Falls Inc | 7618876590 | 70 |
| Teton Radiology Diagnostic A Series Of Teton Group Enterprise | 1254436959 | 33 |
| Teton Radiology Madison Llc | 6901958024 | 31 |
| Cache Valley Vein | 5294069563 | 8 |
| Medical Imaging Associates Of Idaho Falls Inc | 7618876590 | 70 |
| Teton Radiology Diagnostic A Series Of Teton Group Enterprise | 1254436959 | 33 |
| Teton Radiology Madison Llc | 6901958024 | 31 |
| Cache Valley Vein | 5294069563 | 8 |
| Teton Radiology Diagnostic A Series Of Teton Group Enterprise | 1254436959 | 33 |
| Teton Radiology Madison Llc | 6901958024 | 31 |
News Archive
PBS NewsHour examines how the Canadian organization MEDA is using text messages to track malaria supplies in local clinics and retailers in Tanzania. The piece includes a related video featuring a MEDA employee giving a tour of the program (Cheers, 7/22).
Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.
The latest study co-led by a CU School of Medicine researcher has confirmed that a Gene Expression Classifier (GEC) test can drastically reduce the problem of unnecessary surgeries in thyroid nodule assessment.
Researchers in the biological sciences department in the Faculty of Science at the University of Calgary have revealed how white blood cells move to infection or inflammation in the body; findings which could help lead to developing drug therapies for immune system disorders.
Palatin Technologies, Inc. today announced that a second phase I clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist under development for the treatment of obesity, has commenced.
› Verified 4 days ago
| Entity Name | Medical Imaging Associates Of Idaho Falls Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740225531 PECOS PAC ID: 7618876590 Enrollment ID: O20040108000883 |
News Archive
PBS NewsHour examines how the Canadian organization MEDA is using text messages to track malaria supplies in local clinics and retailers in Tanzania. The piece includes a related video featuring a MEDA employee giving a tour of the program (Cheers, 7/22).
Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.
The latest study co-led by a CU School of Medicine researcher has confirmed that a Gene Expression Classifier (GEC) test can drastically reduce the problem of unnecessary surgeries in thyroid nodule assessment.
Researchers in the biological sciences department in the Faculty of Science at the University of Calgary have revealed how white blood cells move to infection or inflammation in the body; findings which could help lead to developing drug therapies for immune system disorders.
Palatin Technologies, Inc. today announced that a second phase I clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist under development for the treatment of obesity, has commenced.
› Verified 4 days ago
| Entity Name | Teton Radiology Diagnostic A Series Of Teton Group Enterprise |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013085604 PECOS PAC ID: 1254436959 Enrollment ID: O20070424000540 |
News Archive
PBS NewsHour examines how the Canadian organization MEDA is using text messages to track malaria supplies in local clinics and retailers in Tanzania. The piece includes a related video featuring a MEDA employee giving a tour of the program (Cheers, 7/22).
Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.
The latest study co-led by a CU School of Medicine researcher has confirmed that a Gene Expression Classifier (GEC) test can drastically reduce the problem of unnecessary surgeries in thyroid nodule assessment.
Researchers in the biological sciences department in the Faculty of Science at the University of Calgary have revealed how white blood cells move to infection or inflammation in the body; findings which could help lead to developing drug therapies for immune system disorders.
Palatin Technologies, Inc. today announced that a second phase I clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist under development for the treatment of obesity, has commenced.
› Verified 4 days ago
| Entity Name | Teton Radiology Madison Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407081060 PECOS PAC ID: 6901958024 Enrollment ID: O20090720000575 |
News Archive
PBS NewsHour examines how the Canadian organization MEDA is using text messages to track malaria supplies in local clinics and retailers in Tanzania. The piece includes a related video featuring a MEDA employee giving a tour of the program (Cheers, 7/22).
Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.
The latest study co-led by a CU School of Medicine researcher has confirmed that a Gene Expression Classifier (GEC) test can drastically reduce the problem of unnecessary surgeries in thyroid nodule assessment.
Researchers in the biological sciences department in the Faculty of Science at the University of Calgary have revealed how white blood cells move to infection or inflammation in the body; findings which could help lead to developing drug therapies for immune system disorders.
Palatin Technologies, Inc. today announced that a second phase I clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist under development for the treatment of obesity, has commenced.
› Verified 4 days ago
| Entity Name | Teton Vascular Institute Of Pocatello A Series Of Teton Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508224379 PECOS PAC ID: 8921306846 Enrollment ID: O20160409000003 |
News Archive
PBS NewsHour examines how the Canadian organization MEDA is using text messages to track malaria supplies in local clinics and retailers in Tanzania. The piece includes a related video featuring a MEDA employee giving a tour of the program (Cheers, 7/22).
Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.
The latest study co-led by a CU School of Medicine researcher has confirmed that a Gene Expression Classifier (GEC) test can drastically reduce the problem of unnecessary surgeries in thyroid nodule assessment.
Researchers in the biological sciences department in the Faculty of Science at the University of Calgary have revealed how white blood cells move to infection or inflammation in the body; findings which could help lead to developing drug therapies for immune system disorders.
Palatin Technologies, Inc. today announced that a second phase I clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist under development for the treatment of obesity, has commenced.
› Verified 4 days ago
| Entity Name | Cache Valley Vein |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831662311 PECOS PAC ID: 5294069563 Enrollment ID: O20231106001459 |
News Archive
PBS NewsHour examines how the Canadian organization MEDA is using text messages to track malaria supplies in local clinics and retailers in Tanzania. The piece includes a related video featuring a MEDA employee giving a tour of the program (Cheers, 7/22).
Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.
The latest study co-led by a CU School of Medicine researcher has confirmed that a Gene Expression Classifier (GEC) test can drastically reduce the problem of unnecessary surgeries in thyroid nodule assessment.
Researchers in the biological sciences department in the Faculty of Science at the University of Calgary have revealed how white blood cells move to infection or inflammation in the body; findings which could help lead to developing drug therapies for immune system disorders.
Palatin Technologies, Inc. today announced that a second phase I clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist under development for the treatment of obesity, has commenced.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John J Strobel, MD 2265 E Sunnyside Rd, Idaho Falls, ID 83404-7598 Ph: (208) 542-5000 | John J Strobel, MD 3100 Channing Way, Idaho Falls, ID 83404-7533 Ph: (208) 529-6111 |
News Archive
PBS NewsHour examines how the Canadian organization MEDA is using text messages to track malaria supplies in local clinics and retailers in Tanzania. The piece includes a related video featuring a MEDA employee giving a tour of the program (Cheers, 7/22).
Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.
The latest study co-led by a CU School of Medicine researcher has confirmed that a Gene Expression Classifier (GEC) test can drastically reduce the problem of unnecessary surgeries in thyroid nodule assessment.
Researchers in the biological sciences department in the Faculty of Science at the University of Calgary have revealed how white blood cells move to infection or inflammation in the body; findings which could help lead to developing drug therapies for immune system disorders.
Palatin Technologies, Inc. today announced that a second phase I clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist under development for the treatment of obesity, has commenced.
› Verified 4 days ago
Dr. Alan B Wray, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3100 Channing Way, Idaho Falls, ID 83404 Phone: 208-227-2600 | |
Dr. James W Taylor, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3100 Channing Way, Idaho Falls, ID 83404 Phone: 208-529-6111 | |
Dr. Neal J Clinger, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3100 Channing Way, Idaho Falls, ID 83404 Phone: 208-227-2600 | |
Dr. Michael Sean Enslow, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3100 Channing Way, Idaho Falls, ID 83404 Phone: 208-529-6111 | |
James P Edlin, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3100 Channing Way, Idaho Falls, ID 83404 Phone: 208-529-6111 | |
Dr. Roderick Jack Willmore, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3100 Channing Way, Idaho Falls, ID 83404 Phone: 208-529-6111 | |
Brett Scott Talbot, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3100 Channing Way, Idaho Falls, ID 83404 Phone: 208-529-6111 |